Loading data for ALDX — first visit, this takes a few seconds.

Aldeyra Therapeutics, Inc. (ALDX)

NasdaqCM: ALDX · 即時價格 · USD

1.47

-0.02 (-1.34%)

收盤價： Sep 02, 2026, 8:00 PM

1.49

+0.01%

盤後: 6:15 PM

提醒

Alert

股價、關鍵數字和最新消息，都在這一頁。

無可用資料

買價	1.08
市值	89.9M
營收 (ttm)	n/a
淨利（ttm）	-23.1M
	1.20
	-0.38
	n/a
	-5.42
P/B (ttm)	2.37
P/S (ttm)	0.00
財報日期	Nov 4, 2026

賣價	1.93
成交量	373,472
20 日平均成交量	1,300,398
開盤價	1.48
前收盤價	1.49
當日區間	1.46 - 1.54
52 週範圍	1.07 - 5.93
分析師	n/a
目標價	n/a
股利	n/a
除息日	n/a

關於 ALDX

Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment of primary vitreoretinal lymphoma and retinitis pigmentosa. T...

[閱讀更多]

產業 Biotechnology

類股 Healthcare

IPO 日期 May 2, 2014

員工 6

證券交易所 NasdaqCM

股票代號 ALDX

網站 https://www.aldeyra.com

完整的公司簡介

財務表現

Aldeyra Therapeutics 在 2025 年的營收為 0，較前一年的 0 增加 undefined%。淨利為 -33.85M，較前期減少 -39.4%。

財務報表

財報驚奇

Aldeyra Therapeutics 已於 Aug 6, 2026 公布季度財報：

營收為 $0 低於預期 $0, 年增 NaN% 成長.
每股盈餘為 -0.09 低於預期 -0.01, 年增 43.75% 成長.

下次財報發布

Aldeyra Therapeutics, Inc. 的下次財報預計於 Nov 4, 2026, 盤中。
分析師預估營收 ... 升級

價格為何變動

新聞動態

2 月前 · Simply Wall St.

CEO, President & Director of Aldeyra Therapeutics Picks Up 18% More Stock

Investors who take an interest in Aldeyra Therapeutics, Inc. ( NASDAQ:ALDX ) should definitely note that the CEO...

3 月前 · MarketBeat

Aldeyra Therapeutics Eyes FDA Feedback as Dry Eye Drug Faces Make-or-Break Moment

Aldeyra Therapeutics (NASDAQ:ALDX) Chief Executive Todd Brady said the company expects near-term feedback from the U.S. Food and Drug Administration on its dry eye disease candidate reproxalap, follow...

3 月前 · Simply Wall St.

3 Promising Penny Stocks With Market Caps Reaching $300M

The market remained flat over the last week, but it is up 26% over the past year, with earnings forecast to grow by 17% annually. Investing in penny stocks—once a buzzword but now more of a niche—can ...

3 月前 · Simply Wall St.

Upstart Holdings Leads These 3 Stocks Estimated To Be Trading Below Fair Value

Over the last 7 days, the United States market has risen by 1.1%, and over the past 12 months, it is up by an impressive 27%, with earnings expected to grow by 17% per annum in the coming years. In th...

3 月前 · Simply Wall St.

3 Stocks That May Be Undervalued According To Analysts In May 2026

Over the last 7 days, the United States market has risen by 1.1%, contributing to a remarkable 27% climb over the past year, with earnings forecasted to grow by 17% annually. In this thriving environm...

第 1 頁，共 2 頁

Aldeyra Therapeutics, Inc. (ALDX)